(Q41455800)

30 September 2017

title

Activity of T-DM1 in Her2-positive breast cancer brain metastases (English)

1 reference

30 September 2017

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26303828%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Anna S Berghoff

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26303828%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

author name string

Rupert Bartsch

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26303828%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Ursula Vogl

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26303828%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Margaretha Rudas

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26303828%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Elisabeth Bergen

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26303828%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Peter Dubsky

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26303828%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Karin Dieckmann

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26303828%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Katja Pinker

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26303828%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Zsuzsanna Bago-Horvath

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26303828%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Arik Galid

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26303828%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Leopold Oehler

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26303828%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Christoph C Zielinski

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26303828%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Michael Gnant

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26303828%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Guenther G Steger

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26303828%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

publication date

25 August 2015

1 reference

Clinical & Experimental Metastasis

30 September 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26303828%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

volume

32

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26303828%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26303828%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

page(s)

729-737

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26303828%20AND%20SRC:MED&resulttype=core&format=json

Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study

1 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10585-015-9740-3

Predicting for activity of second-line trastuzumab-based therapy in her2-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-015-9740-3

Impact of anti-HER2 therapy on overall survival in HER2-overexpressing breast cancer patients with brain metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-015-9740-3

Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-015-9740-3

Brain metastases free survival differs between breast cancer subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-015-9740-3

Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-015-9740-3

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-015-9740-3

DEGRO Practical Guidelines for palliative radiotherapy of breast cancer patients: brain metastases and leptomeningeal carcinomatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-015-9740-3

What is immune privilege (not)?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-015-9740-3

American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-015-9740-3

Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-015-9740-3

Response assessment criteria for brain metastases: proposal from the RANO group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-015-9740-3

Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-015-9740-3

Brain metastases: the HER2 paradigm

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-015-9740-3

Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-015-9740-3

Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-015-9740-3

Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-015-9740-3

Capecitabine and lapatinib uptake in surgically resected brain metastases from metastatic breast cancer patients: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-015-9740-3

Chemotherapy induces regression of brain metastases in breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-015-9740-3

Trastuzumab emtansine for HER2-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-015-9740-3

Breast cancer metastasis to the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-015-9740-3

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-015-9740-3

Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer.

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26303828